Seaport Therapeutics, a startup backed by $100 million in financing, is developing drugs that use a novel delivery approach to address dosing and safety limitations seen in depression drugs. The company’s technology platform, Glyph, leverages the lymphatic system for drug delivery, allowing for better absorption and retention of active ingredients in the body. Seaport’s lead drug candidate, SPT-300, is an oral prodrug of allopregnanolone, a neurosteroid that regulates GABA-A receptors in the body. The company believes that their innovative approach has the potential to offer advantages over current standards of care for conditions like depression and anxiety.
Source link
PureTech Startup Gets $100M to Try For Success Where Sage & Others Fall Short in Depression
